KR102181474B1 - 티아쿠미신 화합물의 조성물 - Google Patents

티아쿠미신 화합물의 조성물 Download PDF

Info

Publication number
KR102181474B1
KR102181474B1 KR1020157021986A KR20157021986A KR102181474B1 KR 102181474 B1 KR102181474 B1 KR 102181474B1 KR 1020157021986 A KR1020157021986 A KR 1020157021986A KR 20157021986 A KR20157021986 A KR 20157021986A KR 102181474 B1 KR102181474 B1 KR 102181474B1
Authority
KR
South Korea
Prior art keywords
thiacumicin
composition
water
fidaxomicin
xanthan gum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157021986A
Other languages
English (en)
Korean (ko)
Other versions
KR20150114498A (ko
Inventor
요시유키 무라카미
히카루 사이토
Original Assignee
아스텔라스 파마 유럽 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47563169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102181474(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아스텔라스 파마 유럽 리미티드 filed Critical 아스텔라스 파마 유럽 리미티드
Publication of KR20150114498A publication Critical patent/KR20150114498A/ko
Application granted granted Critical
Publication of KR102181474B1 publication Critical patent/KR102181474B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020157021986A 2013-01-15 2014-01-14 티아쿠미신 화합물의 조성물 Expired - Fee Related KR102181474B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13075002.9 2013-01-15
EP13075002 2013-01-15
PCT/EP2014/000091 WO2014111254A1 (en) 2013-01-15 2014-01-14 Composition of tiacumicin compounds

Publications (2)

Publication Number Publication Date
KR20150114498A KR20150114498A (ko) 2015-10-12
KR102181474B1 true KR102181474B1 (ko) 2020-11-23

Family

ID=47563169

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157021986A Expired - Fee Related KR102181474B1 (ko) 2013-01-15 2014-01-14 티아쿠미신 화합물의 조성물

Country Status (28)

Country Link
US (1) US9808530B2 (enExample)
EP (1) EP2945613B1 (enExample)
JP (1) JP6338598B2 (enExample)
KR (1) KR102181474B1 (enExample)
CN (1) CN105120840B (enExample)
AR (1) AR094495A1 (enExample)
AU (1) AU2014207083B2 (enExample)
CA (1) CA2904808A1 (enExample)
CY (1) CY1121459T1 (enExample)
DK (1) DK2945613T3 (enExample)
EA (1) EA030049B1 (enExample)
ES (1) ES2705238T3 (enExample)
GE (1) GEP201706769B (enExample)
HR (1) HRP20182110T1 (enExample)
HU (1) HUE041421T2 (enExample)
IL (1) IL239899A0 (enExample)
JO (1) JO3464B1 (enExample)
LT (1) LT2945613T (enExample)
MD (1) MD4588C1 (enExample)
NZ (1) NZ710875A (enExample)
PL (1) PL2945613T3 (enExample)
PT (1) PT2945613T (enExample)
RS (1) RS58119B1 (enExample)
SI (1) SI2945613T1 (enExample)
TW (1) TWI646962B (enExample)
UA (1) UA117004C2 (enExample)
WO (1) WO2014111254A1 (enExample)
ZA (1) ZA201505048B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181756T1 (hr) * 2014-05-09 2018-12-28 Astellas Pharma Europe Ltd. Režim liječenja sa spojem tiakumicina
CN110037992B (zh) * 2019-05-28 2021-05-28 杭州华东医药集团新药研究院有限公司 一种稳定的非达霉素组合物
CN116715678B (zh) * 2023-06-12 2025-09-30 中国科学院成都生物研究所 一种吲哚糖碳苷类大环化合物及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008091518A1 (en) 2007-01-19 2008-07-31 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
WO2008091554A1 (en) 2007-01-22 2008-07-31 Optimer Pharmaceuticals, Inc. Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
US20080193548A1 (en) 2007-02-09 2008-08-14 Claudio Zanichelli Pharmaceutical Compositions for Oral Administration in the Form of Stabilised Aqueous Suspensions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3000792A (en) 1957-05-21 1961-09-19 Merck & Co Inc Antibiotic adsorption process
GB1458512A (en) 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4632902A (en) 1981-08-20 1986-12-30 Becton, Dickinson And Company Method for detecting biological activity in a body fluid
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
CA2384523C (en) 1991-03-04 2007-01-09 Bayer Corporation Automated analyzer
US5583115A (en) 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US5767096A (en) 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
PL193229B1 (pl) 1996-11-18 2007-01-31 F Biotechnologische Forschung Epotylon C, epotylon D, epotylon E i epotylon F, sposób biotransformacji epotylonu A, sposób biotransformacji epotylonu B oraz środek leczniczy
JP2000072760A (ja) 1998-06-19 2000-03-07 Ajinomoto Co Inc 新規シストチアゾール類縁体
JP2000053514A (ja) 1998-08-06 2000-02-22 Aquas Corp レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法
JP2000239266A (ja) 1999-02-17 2000-09-05 Ajinomoto Co Inc 新規ポリエン系抗生物質
CA2404938C (en) 2000-04-28 2011-11-01 Kosan Biosciences, Inc. Production of polyketides
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
EP2860241A1 (en) 2002-07-29 2015-04-15 Optimer Pharmaceuticals, Inc. Tiacumicin production
US20070105791A1 (en) 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
AU2003301121A1 (en) 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
JP4640821B2 (ja) 2003-07-24 2011-03-02 塩野義製薬株式会社 難水溶性薬物を含むドライシロップ剤
JP3881640B2 (ja) 2003-08-08 2007-02-14 塩野義製薬株式会社 ロラタジンを含むドライシロップ剤
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
PL2070530T3 (pl) 2004-05-14 2016-06-30 Merck Sharp & Dohme Leczenie chorób związanych ze stosowaniem antybiotyków
CA2596387C (en) 2005-01-31 2012-11-20 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
WO2006114709A1 (en) * 2005-04-25 2006-11-02 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
CN102503994A (zh) 2005-10-21 2012-06-20 奥普蒂姆药物公司 治疗艰难梭菌相关的腹泻的方法
ZA200905337B (en) 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
JP5608880B2 (ja) * 2010-02-09 2014-10-22 林兼産業株式会社 嚥下困難者用高栄養ゼリー食品
CN102030791B (zh) 2010-10-28 2013-01-23 中国科学院南海海洋研究所 四种台勾霉素类化合物及其制备方法和在制备抗菌药物中的应用
CN102115757B (zh) 2010-12-14 2015-10-28 中国科学院南海海洋研究所 台勾霉素的生物合成基因簇及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008091518A1 (en) 2007-01-19 2008-07-31 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
WO2008091554A1 (en) 2007-01-22 2008-07-31 Optimer Pharmaceuticals, Inc. Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
US20080193548A1 (en) 2007-02-09 2008-08-14 Claudio Zanichelli Pharmaceutical Compositions for Oral Administration in the Form of Stabilised Aqueous Suspensions

Also Published As

Publication number Publication date
WO2014111254A1 (en) 2014-07-24
PL2945613T3 (pl) 2019-05-31
MD4588C1 (ro) 2019-03-31
TW201440775A (zh) 2014-11-01
HRP20182110T1 (hr) 2019-02-22
TWI646962B (zh) 2019-01-11
DK2945613T3 (en) 2019-01-14
JP6338598B2 (ja) 2018-06-06
CY1121459T1 (el) 2020-05-29
RS58119B1 (sr) 2019-02-28
MD20150070A2 (ro) 2016-01-31
KR20150114498A (ko) 2015-10-12
EA030049B1 (ru) 2018-06-29
UA117004C2 (uk) 2018-06-11
NZ710875A (en) 2019-10-25
AU2014207083A1 (en) 2015-08-27
SI2945613T1 (sl) 2019-02-28
EP2945613A1 (en) 2015-11-25
US9808530B2 (en) 2017-11-07
JO3464B1 (ar) 2020-07-05
EA201591226A1 (ru) 2016-01-29
PT2945613T (pt) 2019-01-17
ZA201505048B (en) 2020-05-27
EP2945613B1 (en) 2018-10-10
GEP201706769B (en) 2017-11-10
MD4588B1 (ro) 2018-08-31
IL239899A0 (en) 2015-08-31
LT2945613T (lt) 2019-01-10
ES2705238T3 (es) 2019-03-22
CN105120840B (zh) 2019-03-22
CN105120840A (zh) 2015-12-02
AR094495A1 (es) 2015-08-05
US20160045603A1 (en) 2016-02-18
AU2014207083B2 (en) 2018-03-29
CA2904808A1 (en) 2014-07-24
JP2016505026A (ja) 2016-02-18
HUE041421T2 (hu) 2019-05-28

Similar Documents

Publication Publication Date Title
KR101568681B1 (ko) 안정화된 카리스바메이트 소아용 현탁액
US6861413B2 (en) Stable non-dihydrate azithromycin oral suspensions
KR102181474B1 (ko) 티아쿠미신 화합물의 조성물
CN108430469A (zh) St-246(特考韦瑞一水合物)混悬制剂
CN105125570A (zh) 一种含硫氰酸红霉素药物组合物及其制备方法
KR101595107B1 (ko) 플라보이드 분획 및 잔탄 검을 포함하는 경구 현탁액 형태의 약학 조성물
RU2325149C2 (ru) Стабильные пероральные суспензии недигидратного азитромицина
WO2024132369A1 (en) Pharmaceutical formulations of tafamidis
JP2021533144A (ja) 疼痛及び／又は発熱を予防及び／又は治療するための薬物、組成製品及びその応用
CN104434860A (zh) 包合工艺制备的盐酸氨溴索渗透泵型药物组合物
US10137141B2 (en) Treatment regimen tiacumicin compound
JP5650427B2 (ja) 医薬用ゼリー組成物
CN1822858A (zh) 稳定的非二水合阿奇霉素口服混悬液
KR20160079954A (ko) 액상으로 약물을 분산시킨 필름형태의 약제학적 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20231117

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20231117